Gilead Sciences Company Profile

Aggregated data from the web about Gilead Sciences

Company Name	Gilead Sciences
Website	https://www.gilead.com
Snippet	WebJanuary 22, 2024. Gilead Provides Update on Phase 3 EVOKE-01 Study. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Type	Public
Founded	1987
Revenue	US$27.31 billion[2] (2021)
Industry	Pharmaceutics, Biotechnology
Products	AmBisome, Atripla, Biktarvy, Complera, Cayston, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Lexiscan, Macugen, Odefsey, Ranexa, Sovaldi, Stribild, Tamiflu, Truvada, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta, Zydelig
Traded as	Nasdaq: GILD, NASDAQ Biotechnology Component, NASDAQ-100 Component, S&P 100 Component, S&P 500 Component
Key people	Daniel O'Day(CEO and Chairman)[1], Andrew Dickinson(CFO)[1], Tomáš Cihlář(Vice president, andSenior Director, Biology)
Net income	US$6.23 billion[2] (2021)
Area served	Worldwide
Headquarters	Foster City, California, United States
Total assets	US$67.95 billion[2] (2021)
Total equity	US$21.06 billion[2] (2021)
Operating income	US$9.92 billion[2] (2021)
Number of employees	14,400[2] (2021)

Gilead Sciences is part of the United States company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.